BlackRock, Inc. Amends Schedule 13G/A for EyePoint Pharmaceuticals, Inc.

BlackRock, Inc. has filed an amendment to its Schedule 13G/A for EyePoint Pharmaceuticals, Inc., reporting a 6.5% ownership of the company's common stock as of September 30, 2025. The filing indicates that BlackRock beneficially owns 4,485,402 shares, with sole voting power over 4,383,489 shares and sole dispositive power over all 4,485,402 shares. The filing also notes that various persons have the right to receive dividends or direct the sale of the common stock, but no single person's interest exceeds 5% of the total outstanding shares. The amendment was signed by Spencer Fleming, Managing Director, on October 17, 2025.